ANKHD1

Across TCGA pan-cancer cohorts, ANKHD1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANKHD1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANKHD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKHD1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ANKHD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.598	0.882	.004	37	view →
LUAD	OS	Tertile	All	1.000	0.605	.016	10	view →
PDAC	OS	Median	II,III,IV	0.973	0.788	.020	4	view →
UCEC	DFS	Median	All	0.969	0.842	.006	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ANKHD1–CCRCC (DFS)

Open the CCRCC breakdown →